Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2012 Feb;69(2):341-50.
doi: 10.1007/s00280-011-1697-6. Epub 2011 Jul 8.

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

R Thertulien  1 , G M Manikhas, L Y Dirix, J B Vermorken, K Park, M M Jain, J J Jiao, J Natarajan, T Parekh, P Zannikos, A P Staddon
Affiliations
Controlled Clinical Trial

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

R Thertulien et al. Cancer Chemother Pharmacol. 2012 Feb.

Abstract

Purpose: The primary objective of this study was to access the potential effects of trabectedin on the QT/QTc interval in patients with locally advanced or metastatic solid tumors.

Methods: Patients (n = 75) who had received ≤3 previous lines of chemotherapy and had either relapsed or had progressive disease were enrolled. Patients were administered 3-h intravenous infusions of placebo (saline) on day 1 and trabectedin (1.3 mg/m(2)) on day 2. Time-matched serial triplicate ECG recordings and pharmacokinetic blood samples were collected over 24 h on both days. Heart rate corrected mean QT intervals and changes from predose baseline in QTc (ΔQTc) were assessed. The difference in ΔQTc between trabectedin and placebo was calculated at each time point (ΔΔQTc).

Results: The upper limits of the 90% confidence interval for ΔΔQTcF and ΔΔQTcB at all time points were less than the prespecified noninferiority margin of 10 ms (≤6.65 ms). No patient had a QTc > 500 ms or a time-matched increase from baseline in QTc > 60 ms at any time point. Regression analyses indicated ΔΔQTc was poorly correlated with trabectedin concentration. No adverse events suggestive of proarrhythmic potential were reported.

Conclusion: Trabectedin did not prolong the QTc interval. Safety and pharmacokinetic profiles of trabectedin were similar to that observed in other ovarian and breast cancer studies.

Trial registration: ClinicalTrials.gov NCT00786838.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Placebo-adjusted least square mean (±90% confidence interval) change from baseline in QTc (ΔΔQTc) intervals following treatment with a single dose of trabectedin 1.3 mg/m2 (3-h infusion) in patients with advanced solid tumor malignancies
Fig. 2
Fig. 2
Correlation between placebo-adjusted change from baseline in QTc (ΔΔQTc) versus concentrations of trabectedin in plasma at corresponding time points following treatment with a single dose of trabectedin 1.3 mg/m2 (3-h infusion) in patients with advanced solid tumor malignancies
See this image and copyright information in PMC

References

    1. Boudou L, Baconnier M, Blay J-Y, Lombard-Bohas C, Cassier PA. Trabectedin for the management of soft-tissue sarcoma. Expert Rev Anticancer Ther. 2009;9:727–737. doi: 10.1586/era.09.28. - DOI - PubMed
    1. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 2007;67:2257–2276. doi: 10.2165/00003495-200767150-00009. - DOI - PubMed
    1. EMEA Yondelis (2010) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct_Informa.... Accessed 27 Aug 2010
    1. Perez-Ruixo JJ, Zannikos P, Hirankarn S, Stuyckens K, Ludwig EA, Soto-Matos A, Lopez-Lazaro L, Owen JS. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet. 2007;46:867–884. doi: 10.2165/00003088-200746100-00005. - DOI - PubMed
    1. Beumer JH, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743) Curr Clin Pharmacol. 2009;4:38–42. doi: 10.2174/157488409787236047. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources